April 2, 2018 / 12:54 PM / 6 months ago

BRIEF-Sellas Life Sciences Announces Positive Interim Data From Phase 2B Neuvax Clinical Trial In Combination With Herceptin

April 2 (Reuters) - Sellas Life Sciences Group Inc:

* SELLAS LIFE SCIENCES ANNOUNCES POSITIVE INTERIM DATA FROM PHASE 2B NEUVAX™ (NELIPEPIMUT-S) CLINICAL TRIAL IN COMBINATION WITH HERCEPTIN® IN HER2 1+/2+ BREAST CANCER PATIENTS

* CLINICALLY AND STATISTICALLY SIGNIFICANT EFFICACY IN TRIPLE NEGATIVE BREAST CANCER

* CLINICALLY MEANINGFUL AND STATISTICALLY SIGNIFICANT DIFFERENCE WAS FOUND BETWEEN TWO ARMS IN COHORT OF PATIENTS​

* ‍ADDITION OF NEUVAX TO HERCEPTIN DID NOT RESULT IN ANY ADDITIONAL CARDIOTOXICITY COMPARED TO HERCEPTIN ALONE​

* TOLERATED​

* SPECIFIED INTERIM ANALYSIS SHOWED AN ADVERSE EVENT PROFILE WITH NO NOTABLE DIFFERENCES BETWEEN TREATMENT ARMS​

* ‍DSMB RECOMMENDED TO SEEK REGULATORY GUIDANCE BY FDA FOR FURTHER DEVELOPMENT OF COMBINATION OF NEUVAX + HERCEPTIN IN TNBC​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below